Mvasi

(Bevacizumab-awwb)

Mvasi

Drug updated on 10/23/2023

Dosage FormInjection (intravenous: 100 mg/4 mL (25 mg/mL) or 400 mg/16 mL (25 mg/mL))
Drug ClassVascular endothelial growth factor inhibitor
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment.
  • For the treatment of metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.
  • For the treatment of unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment.
  • For the treatment of recurrent glioblastoma in adults.
  • For the treatment of metastatic renal cell carcinoma in combination with interferon-alfa.
  • For the treatment of persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan.
  • For the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by MVASI as a single agent, for stage III or IV disease following initial surgical resection; in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens; in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by MVASI as a single agent, for platinumsensitive recurrent disease.

Product Monograph / Prescribing Information

Document TitleYearSource
Mvasi (bevacizumab-awwb) Prescribing Information.2023Amgen, Inc., Thousand Oaks, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis.2023BMC Cancer
Different doses of bevacizumab in combination with chemotherapy for advanced colorectal cancer: a meta-analysis and Bayesian analysis.2023International Journal of Colorectal Disease
Efficacy and safety of bevacizumab in pretreated metastatic breast cancer : a systematic review and meta-analysis.2022Oncology Research and Treatment
Association between bevacizumab with cancer drug therapies and drug-induced interstitial lung disease in patients with solid tumor: a systematic review and meta-analysis of randomized clinical trials.2022Critical Reviews in Oncology/Hematology
The efficacy and safety of bevacizumab combined with FOLFOX regimen in the treatment of advanced colorectal cancer: a systematic review and meta-analysis.2021Medicine
The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: a meta-analysis of randomized controlled trials.2021Journal of Clinical Pharmacy and Therapeutics
The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: a systematic review and meta-analysis.2021Gynecologic Oncology
Maintenance treatment of combination with bevacizumab vs single agent for advanced non-squamous non-small cell lung cancer: a systematic review and meta-analysis.2021Medicine
Reliability and toxicity of bevacizumab for neurofibromatosis type 2-related vestibular schwannomas: a systematic review and meta-analysis.2021American Journal of Otolaryngology
Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive recurrent ovarian cancer: a network meta-analysis.2020International Journal of Molecular Medicine
Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis t ype 2: a systematic review and meta-analysis of treatment outcomes.2019Journal of Neuro-Oncology
Comparative toxicities of neoadjuvant chemotherapy with or without bevacizumab in HER2-negative breast cancer patients: a meta-analysis.2019Annals of Pharmacotherapy

Clinical Practice Guidelines